12:00 AM
 | 
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aranesp darbepoetin alfa hematology data

A meta-analysis of 6 double-blind studies in 2,122 patients with non-myeloid tumors receiving chemotherapy showed that Aranesp increased the risk of thromboembolic events vs. placebo (8% vs. 5%), but decreased the risk of receiving 1 or more transfusions. Transfusions were associated with a...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >